Related Experiment Video
Updated: Aug 8, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Rosiglitazone-induced immune thrombocytopenia
Xiaojing Liu1, Tao Huang, Mervyn A Sahud
1Blood Research Institute, Oakland, California 92690, USA.
Platelets
|May 17, 2006
Summary
This study details the first reported case of immune thrombocytopenia caused by the anti-diabetic drug rosiglitazone. The patient developed severe thrombocytopenia due to rosiglitazone-induced antibodies targeting platelet glycoproteins.
Area of Science:
- Immunology
- Pharmacology
- Hematology
Background:
- Rosiglitazone, a thiazolidinedione (TZD), effectively treats type 2 diabetes.
- Thiazolidinediones are a class of anti-diabetic medications.
- Type 2 diabetes management often involves oral hypoglycemic agents.
Observation:
- A patient developed acute, severe thrombocytopenia following exposure to rosiglitazone maleate (Avandia).
- Patient serum demonstrated rosiglitazone-induced antibodies via flow cytometry (binding ratio 5.93 MFI).
- The identified antibody bound to glycoprotein (GP) IIb-IIIa and GP Ib/IX complexes.
Findings:
- MAIPA assays confirmed antibody binding to GP IIb-IIIa and GP Ib/IX complexes.
- Immunoprecipitation studies showed rosiglitazone-dependent precipitation of GPIIb/IIIa and GP Ib/IX.
- Evidence suggests a specific immune response triggered by rosiglitazone.
Implications:
- This case establishes rosiglitazone-induced immune thrombocytopenia as a potential adverse drug reaction.
- Highlights the importance of considering drug-induced thrombocytopenia in patients on rosiglitazone.
- Contributes to understanding drug-induced immune reactions involving platelet glycoproteins.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...